



Amendments to the Claims

1. (Currently Amended) A ~~compound prodrug of a hydroxamic acid derivative histone deacetylase (HDAC) inhibitor~~, represented by the structure of formula 1:




wherein R is a residue of a hydroxamic acid derivative histone deacetylase inhibitor; and R_a is represented by the structure:



wherein R_b and R_c are independently of each other a hydrogen or an unsubstituted or substituted alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heterocyclyl, heteroaryl, alkylaryl, alkylcycloalkyl, alkylheterocyclyl, alkylheteroaryl or an amino acid residue; and R_d is hydrogen or an amino protecting group;


or a pharmaceutically acceptable salt, hydrate, solvate, polymorph or any combination thereof.

2. (Currently Amended) The ~~compound prodrug~~ according to claim 1, wherein R_b and R_c are independently of each other a hydrogen, methyl, ethyl, isopropyl, butyl, isobutyl, sec-butyl, t-butyl, phenyl, benzyl, alkylphenyl, naphthyl or pyridyl.
3. (Currently Amended) The ~~compound prodrug~~ according to claim 1, wherein R_a is selected from the group consisting of:




and wherein m is an integer of 1 to 10.

4. (Currently Amended) The compound ~~prodrug~~ according to claim 1, represented by the structure:




wherein each of R₁ and R₂ are independently the same as or different from each other and are a hydrogen atom, a hydroxyl group, a substituted or unsubstituted, branched or unbranched alkyl, alkenyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, alkylcycloalkyl, alkylaryl, alkylheterocyclyl, alkylheteroaryl, arylalkyloxy, aryloxy, or pyridine group, or R₁ and R₂ are bonded together to form a nitrogen containing heterocyclic ring optionally containing one or more additional heteroatoms, and n is an integer of 4 to 8.

5. (Currently Amended) The compound ~~prodrug~~ according to claim 1, represented by the structure:



wherein n is an integer of 4 to 8.

6. (Currently Amended) The compound ~~prodrug~~ according to claim 1, represented by the structure:




7. Cancelled.


(5)

8. Cancelled.

9. (Currently Amended) The compound prodrug according to claim 1, represented by the structure:




10. (Currently Amended) The compound prodrug according to claim 1, represented by the structure:




wherein R₁ is a substituted or unsubstituted phenyl, piperidino, thiazolyl, 2-pyridinyl, 3- pyridinyl or 4-pyridinyl and n is an integer of 4 to 8.

11. (Currently Amended) The compound prodrug according to claim 1, represented by the structure:



wherein R₁ is a substituted or unsubstituted phenyl, piperidino, thiazolyl, 2-pyridinyl, 3- pyridinyl or 4-pyridinyl and n is an integer of 4 to 8.


12. (Currently Amended) The compound prodrug according to claim 1, represented by the structure:




wherein A is an amide moiety, R₁ and R₂ are each selected from substituted or unsubstituted aryl, arylalkyl, naphthyl, cycloalkyl, cycloalkylamino, pyridineamino, piperidino, 9-purine-6-amino, thiazoleamino, hydroxyl, branched or unbranched alkyl, alkenyl, alkyloxy, aryloxy, arylalkyloxy, pyridyl, quinolinyl or isoquinolinyl; and n is an

integer of 3 to 10.


13. (Currently Amended) The compound prodrug according to claim 12, represented by the structure:



14. (Currently Amended) The compound prodrug according to claim 12, represented by the structure:




15. (Currently Amended) The compound prodrug according to claim 1, represented by the structure:




wherein A is an amide moiety, R₁ and R₂ are each selected from substituted or unsubstituted aryl, arylalkyl, naphthyl, cycloalkyl, cycloalkylamino, pyridineamino, piperidino, 9-purine-6-amino, thiazoleamino, hydroxyl, branched or unbranched alkyl, alkenyl, alkyloxy, aryloxy, arylalkyloxy, pyridyl, quinolinyl or isoquinolinyl; R₃ is hydrogen, a halogen, a phenyl or a cycloalkyl moiety and n is an integer of 3 to 10.

16. (Currently Amended) The compound prodrug according to claim 15, represented by the structure:




17. (Currently Amended) The compound prodrug according to claim 15, represented by the structure:




wherein n is an integer from about 3 to 10.

18. (Currently Amended) The compound prodrug according to claim 1, represented by the structure:




-wherein L is a linker selected from the group consisting of an amide moiety, O-, -S-, -NH-, NR-, -CH₂-, -(CH₂)_p-, -(CH=CH)-, phenylene, cycloalkylene, or any combination thereof wherein R is a substituted or unsubstituted C₁-C₃ alkyl; and wherein each of R₁ and R₂ are independently a substituted or unsubstituted aryl, arylalkyl, naphthyl, cycloalkyl, cycloalkylamino, pyridineamino, piperidino, 9-purine-6-amino, thiazoleamino, hydroxyl, branched or unbranched alkyl, alkenyl, alkoxy, aryloxy, arylalkoxy, pyridyl, quinolinyl or isoquinolinyl; p is an integer of 0 to 10.


19. (Currently Amended) The compound prodrug according to claim 18, represented by the structure:



20. (Currently Amended) The compound prodrug according to claim 18, represented by the structure:



21. (Currently Amended) The compound prodrug according to claim 1, represented by the structure:



wherein


n is 2, 3, 4, 5, 6, 7 or 8;

q is 0 or 1;

p₁ and p₂ are independently of each other 0 or 1;

R₁ and R₂ are independently of each other an unsubstituted or substituted aryl, heteroaryl, cycloalkyl, heterocyclyl, alkylaryl, alkylheteroaryl, alkylcycloalkyl or alkylheterocyclyl; or when p₁ and p₂ are both 0, R₁ and R₂ together with the -CH₂-N-CH₂- group to which they are attached can also represent a nitrogen-containing heterocyclic ring; or when at least one of p₁ or p₂ is not 0, R₁ or R₂ or both can also represent hydrogen or alkyl.

22. (Currently Amended) The compound prodrug according to claim 1, represented by the structure:




wherein

n is 2, 3, 4, 5, 6, 7 or 8;

R₁ and R₂ are independently of each other a hydrogen or an unsubstituted or substituted alkyl, aryl, heteroaryl, cycloalkyl, heterocyclyl, alkylaryl, alkylheteroaryl, alkylcycloalkyl or alkylheterocyclyl.

23. (Currently Amended) The compound prodrug according to claim 1, represented by the structure:




wherein

n is 2, 3, 4, 5, 6, 7 or 8;

R₁ and R₂ are independently of each other a hydrogen or an unsubstituted or substituted alkyl, aryl, heteroaryl, cycloalkyl, heterocyclyl, alkylaryl, alkylheteroaryl, alkylcycloalkyl or alkylheterocyclyl.

24. (Currently Amended) The compound prodrug according to claim 1, represented by the structure:




(32)

wherein

n is 2, 3, 4, 5, 6, 7 or 8;

R₁ and R₂ are independently of each other an unsubstituted or substituted aryl, heteroaryl, cycloalkyl, heterocyclyl, alkylaryl, alkylheteroaryl, alkylcycloalkyl or alkylheterocyclyl; or R₁ and R₂ together with the -CH₂-N-CH₂- group to which they are attached can also represent a nitrogen-containing heterocyclic ring.

25. (Currently Amended) The compound ~~prodrug~~ according to claim 1, represented by the structure:




wherein


n is 2, 3, 4, 5, 6, 7 or 8;

R₁ and R₂ are independently of each other an unsubstituted or substituted aryl, heteroaryl, cycloalkyl, heterocyclyl, alkylaryl, alkylheteroaryl, alkylcycloalkyl or alkylheterocyclyl; or R₁ and R₂ together with the -CH₂-N-CH₂- group to which they are attached can also represent a nitrogen-containing heterocyclic ring.

26. (Currently Amended) The compound ~~prodrug~~ according to claim 1, represented by the structure:




wherein A is alkyl, aryl or a group selected from




wherein R_1 - R_{16} are independently of each other a hydrogen or an unsubstituted or substituted alkyl, aryl, cycloalkyl, heterocyclyl, alkylaryl, alkylcycloalkyl or alkylheterocyclyl; or one or more of R_1 and R_2 , R_6 and R_7 , and R_{11} and R_{12} , together with the nitrogen atom to which they are attached, form a nitrogen-containing heterocyclic ring; and l , p and q are independently of each other 0, 1 or 2.

27. (Currently Amended) The compound ~~prodrug~~ according to claim 1, represented by the structure:




wherein

A is alkyl, aryl or a group selected from:



wherein R₁-R₁₆ are independently of each other a hydrogen or an unsubstituted or substituted alkyl, aryl, cycloalkyl, heterocyclyl, alkylaryl, alkylcycloalkyl or alkylheterocyclyl; or one or more of R₁ and R₂, R₆ and R₇, and R₁₁ and R₁₂, together with the nitrogen atom to which they are attached, form a nitrogen-containing heterocyclic ring;

B is



n is 0 or 1; and


l, p and q are independently of each other 0, 1 or 2.

28. (Currently Amended) A pharmaceutical composition comprising the ~~compound~~ prodrug of claim 1 or a pharmaceutically acceptable salt or hydrate thereof, and a pharmaceutically acceptable carrier.

29. (Currently Amended) Use of the prodrug of claim 1 in the manufacture of a medicament A method for the treatment of cancer comprising the step of administering to a mammal a therapeutically effective amount of the compound of claim 1.
30. Cancelled.
31. Cancelled.
32. Cancelled.
33. (New) The compound of claim 1 selected from the group consisting of:
Octanedioic acid phenylamide (7-phenylcarbamoyl-heptanoyloxy)-amide;
Octanedioic acid acetoxy-amide phenylamide;
Octanedioic acid (biphenyl-4-carbonyloxy)-amide phenylamide;
Octanedioic acid benzoyloxy-amide phenylamide;
Octanedioic acid (naphthalene-2-carbonyloxy)-amide phenylamide;
Octanedioic acid (naphthalene-1-carbonyloxy)-amide phenylamide;
Octanedioic acid (3-methoxy-benzoyloxy)-amide phenylamide;
Octanedioic acid (4-methoxy-benzoyloxy)-amide phenylamide;
Octanedioic acid (2-methoxy-benzoyloxy)-amide phenylamide;
Octanedioic acid (4-methyl-benzoyloxy)-amide phenylamide;
Octanedioic acid (4-chloro-benzoyloxy)-amide phenylamide;
Octanedioic acid (3-phenyl-acryloyloxy)-amide phenylamide;
Octanedioic acid phenylamide (pyridine-3-carbonyloxy)-amide;
Octanedioic acid (4-butyl-benzoyloxy)-amide phenylamide;
Octanedioic acid phenylamide (3-phenyl-propionyloxy)-amide;
Octanedioic acid phenylamide (4-phenyl-butyryloxy)-amide;
[1-Benzyl-2-oxo-2-(7-phenylcarbamoyl-heptanoylaminoxy)-ethyl]-carbamic acid benzyl ester;
and
[1-Benzyl-2-oxo-2-(7-phenylcarbamoyl-heptanoylaminoxy)-ethyl]-carbamic acid tert-butyl ester;
Or a stereoisomer thereof;
Or a pharmaceutically acceptable salt thereof;


Or a pharmaceutically acceptable salt of the stereoisomer thereof.

34. (New) The compound of claim 1 that is



or a pharmaceutically acceptable salt thereof.

35. (New) The compound of claim 1 that is



or a pharmaceutically acceptable salt thereof.

36. (New) A pharmaceutical composition comprising the compound of claim 33 and a pharmaceutically acceptable carrier.
37. (New) A method for the treatment of cancer comprising the step of administering to a mammal a therapeutically effective amount of the compound of claim 33.